Pharm'Up 
Rubicon Research Limited has received a single observation in a Form 483 from the United States Food and Drug Administration (US FDA) following an unannounced inspection of its manufacturing facility in Satara, Maharashtra.
Key Details of the Inspection
- Inspection Dates: The inspection took place from October 5 to October 9, 2026, at the facility located in Additional MIDC, Satara, Maharashtra.
- Nature of Observation: The company stated that the single observation is procedural and does not involve data integrity issues. Rubicon Research expressed confidence in resolving the matter collaboratively with the US FDA.
- Inspection Context: This evaluation is part of Rubicon Research’s broader regulatory inspection schedule for its global operations. A successful outcome would mark the company’s third successful unannounced US FDA inspection in fiscal year 2026–27, following inspections at its Toronto R&D facility in April 2026 and its Pithampur manufacturing facility in July 2026.
- Regulatory Meaning: A Form FDA 483 is issued when investigators identify conditions that may violate regulatory standards, but it does not constitute a final agency determination of non-compliance.
About the Author
